Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI-SAVE

Other

• Patients with known CNS metastases at baseline
• Usage of strong CYP3A4 inducers as described in 9.1.2
• Treatment related toxicity for which a dose reduction of osimertinib is indicated
• Patients who are either pregnant, breastfeeding or actively trying to conceive

• Age ≥18 years
• Able to understand the written information and able to give informed consent
• Sufficient knowledge of the local language in order answer the questionnaires
• Locally advanced or metastatic NSCLC with an EGFR exon 19 deletions or exon 21 L858R muta-tions not eligible for curative intent therapy
• Treatment with first-line osimertinib 80 mg QD with or without chemotherapy for at least three months according to standard of care;
• A response on radiologic assessment (response is defined as: - complete or partial response as defined by RECIST 1.1, assessed by the treating physi-cian. - a radiological response according to the treating physician that does not meet the crite-ria for partial response according to RECIST 1.1.)